N-acetylcysteine (NAC) in schizophrenia resistant to clozapine: a double blind randomised placebo controlled trial targeting negative symptoms

BACKGROUND: Clozapine is an effective treatment for a proportion of people with schizophrenia (SZ) who are resistant to the beneficial effects of other antipsychotic drugs. However, anything from 40–60 % of people on clozapine experience residual symptoms even on adequate doses of the medication, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossell, Susan L., Francis, Paul S., Galletly, Cherrie, Harris, Anthony, Siskind, Dan, Berk, Michael, Bozaoglu, Kiymet, Dark, Frances, Dean, Olivia, Liu, Dennis, Meyer, Denny, Neill, Erica, Phillipou, Andrea, Sarris, Jerome, Castle, David J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024434/
https://www.ncbi.nlm.nih.gov/pubmed/27629871
http://dx.doi.org/10.1186/s12888-016-1030-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024434/
https://www.ncbi.nlm.nih.gov/pubmed/27629871
http://dx.doi.org/10.1186/s12888-016-1030-3

Ejemplares similares